Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study
Authors:
- 1 August 2017
- journal article
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 31 (8) , 329-334
Abstract
We assessed the value of screening for cognitive abnormalities in a chronically infected HIV population (N = 388) and investigated the association with clinical correlates. The mean age was 48 years (±11), the majority of the patients were male (89%), the median duration of infection was 6 years [interquartile range (IQR) = 2-12], the median CD count was 600 (IQR = 450-780), and 326 (84%) had a viral load below 200 copies/mL. Screening for cognitive complaints was applied using the three Simioni questions and the international HIV dementia scale (iHDS). Neuropsychological assessment (NPA) included 13 well-validated tests assessing motor speed, concentration, and memory. A total of 69 patients completed the NPA. CD4 (nadir), viral load, combination antiretroviral therapy (cART) duration, and the presence of comorbidities were evaluated for associations with NPA result. A total of 127 (33%) reported cognitive complaints during screening. The sensitivity and specificity of the Simioni questions were 82% and 24%, respectively. Adding the iHDS resulted in a sensitivity of 50% and a specificity of 73%. A CD4 nadir count <50 cells/m3 was associated with an abnormal NPA (p = 0.01). Comorbidities were more prevalent in patients with an abnormal NPA, although not statistically significant (p = 0.276). Age, current CD4, viral load, and cART duration were not associated with abnormal NPA. The authors conclude that current screening strategies are insufficient in detecting HIV-associated neurocognitive disorder. A low CD4 nadir is associated with poor neurocognitive outcome in HIV.Keywords
This publication has 16 references indexed in Scilit:
- Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort StudyNeurology, 2016
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patientsJournal of NeuroVirology, 2015
- Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER StudyClinical Infectious Diseases, 2014
- HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapyNeurology, 2010
- Updated research nosology for HIV-associated neurocognitive disordersNeurology, 2007
- Trail Making Test A and B: Normative data stratified by age and educationArchives of Clinical Neuropsychology, 2004
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- “Mini-mental state”Journal of Psychiatric Research, 1975
- Clinical NeuropsychologyMedical Clinics of North America, 1963